Lupin launches Rivaroxaban oral suspension in US market

Mumbai-based Lupin Limited has launched Rivaroxaban for Oral Suspension, 1 mg/mL, in the United States, a product bioequivalent to Xarelto® for Oral Suspension, 1 mg/mL, from Janssen Pharmaceuticals, Inc.

Rivaroxaban for Oral Suspension is indicated for treating venous thromboembolism (VTE) and reducing recurrent VTE risk in pediatric patients, as well as for thromboprophylaxis in pediatric patients with congenital heart disease after the Fontan procedure. The reference listed drug, Xarelto®, had estimated annual sales of $11 million in the U.S. as of July 2025 (IQVIA MAT).

This development aligns with Lupin's focus on specialty pharmaceutical products and strengthening its position in key therapy areas. The company, headquartered in Mumbai, India, operates across over 100 markets globally.